Wegovy first month results: what to expect before and after week four

What trial data actually shows about the first four weeks

The STEP 1 trial enrolled 1,961 adults with obesity or overweight and at least one weight-related condition, running for 68 weeks. Weight loss in month one was not the headline: the trial reported its results at the end, with an average body-weight reduction of roughly 15% for those receiving 2.4 mg semaglutide. But within that data, the pattern is clear — early weight loss is real, incremental and front-loaded with adjustment rather than rapid loss.

At 0.25 mg, the body is being introduced to the medicine. Gastric emptying slows, appetite signals shift, and most people notice they feel full sooner at meals. For some that translates to a 1–2 kg drop in the first fortnight; for others, very little movement on the scale until the dose steps up. Neither is a sign of failure. The NHS semaglutide medicines page is clear that results take time and that treatment should be reviewed if less than 5% weight loss has occurred by the six-month mark on the maintenance dose.

What month one does reliably produce is a change in relationship with food. Patients consistently report smaller portion sizes feeling satisfying, reduced interest in snacking, and (particularly for people who previously ate past fullness) a new awareness of hunger and satiety cues. These behavioural shifts, compounding over weeks, drive the longer-term numbers.

Why the before-and-after picture at week four looks different for everyone

Several factors shape what the scales say at the end of month one. Baseline weight matters: a higher starting BMI tends to produce larger absolute losses early on, even if the percentage is similar. Dietary changes alongside treatment matter too. The STEP 1 protocol included a reduced-calorie diet and activity support; Wegovy's licence requires it to be used alongside both. People who make meaningful food adjustments in parallel often see more movement in week one through four.

Nausea is the other variable. It is the most reported side effect in the first month, and when it is significant it can temporarily reduce food intake sharply (which shows on the scale) or, in some people, make eating difficult enough that they lose confidence in the treatment. Both responses are normal and usually transient. Starting slowly and eating smaller, lower-fat meals can help considerably; the prescriber's role includes monitoring this and deciding when escalation is clinically appropriate.

Fluid changes also contribute to early readings. Some of the weight logged in week one or two reflects reduced water retention rather than fat loss, which is why the four-week point is better understood as a baseline check than a final verdict. If you are wondering what Wegovy first month results typically look like, the two-month point offers useful context, and the two-month results picture gives a sense of how the trajectory develops after the first dose step.

What a realistic before-and-after looks like at 30 days

Setting expectations clearly matters here. A 1–3 kg reduction in month one is a reasonable average to carry into conversations, not a guarantee, and not a ceiling. Some people lose more; a small number lose very little in the first four weeks and then accelerate sharply once the dose increases. Weight-loss medicines are not linear.

Visible physical changes at 30 days are usually subtle. Clothes may fit marginally differently; some people notice a slight reduction in bloating alongside the dietary changes. Dramatic before-and-after transformations shared online almost always reflect three to six months of treatment, not one. Framing week four as progress rather than proof keeps expectations grounded and motivation intact.

For context on what the full results trajectory looks like, the broader Wegovy results page covers the evidence from multiple timepoints. And if you are weighing how long the medicine takes to produce meaningful change, our page on how long Wegovy takes to work addresses the dose-by-dose timeline directly.

One practical note: some people time their first order around the start of the month, payday, a new routine, a Monday. That is fine. What matters clinically is consistency after the first pen arrives, not the calendar date it starts.

Starting Wegovy through a regulated UK service

Wegovy is a prescription-only medicine. There is no legal route to it without a clinical assessment, and the prescriber who reviews your consultation decides suitability based on your health history, current medicines and BMI, not a checklist or an algorithm. At nume, a GPhC-registered Independent Prescriber reads every consultation the same day it is submitted. The GPhC registration of our pharmacy (number 9012878) is verifiable on the GPhC register.

Treatment is priced transparently and includes the consultation, prescription, medicine and free next-working-day delivery. There are no subscription traps. Every repeat order is clinically re-reviewed before dispatch. If you want to understand the cost alongside the clinical picture, our guide to Wegovy pricing in the UK covers what legitimate treatment typically costs and what to watch for. The Wegovy overview page covers the full treatment picture for anyone earlier in the research stage.

If you are ready to find out whether Wegovy is clinically appropriate for you, the place to start is a free consultation with our prescribing team.

Start your free consultation